


ORIGINAL ARTICLE

Impacts of variants of uncertain significance on parental perceptions of children after prenatal chromosome microarray testing

Preeya Desai¹  | Hannah Haber² | Jessica Bulafka³ | Amita Russell⁴ | Rebecca Clifton⁵ | Julia Zachary⁵ | Seonjoo Lee^{6,7} | Tianshu Feng⁶ | Ronald Wapner⁴ | Catherine Monk^{1,4,8} | Wendy K. Chung^{3,9}

¹New York State Psychiatric Institute, New York, NY, USA

²Columbia University, New York, NY, USA

³Department of Pediatrics, Columbia University, New York, NY, USA

⁴Department of Obstetrics & Gynecology, Columbia University, New York, NY, USA

⁵George Washington University, Washington, DC, USA

⁶Division of Biostatistics, New York State Psychiatric Institute, New York, NY, USA

⁷Department of Biostatistics, Columbia University, New York, NY, USA

⁸Department of Psychiatry, Columbia University, New York, NY, USA

⁹Department of Medicine, Columbia University, New York, NY, USA

Correspondence

Wendy Chung, Department of Pediatrics, Columbia University, 1150 St. Nicholas Avenue, Room 620, New York, NY 10032, 212-851-5313, USA.
Email: wkc15@columbia.edu

Funding information

National Institute of Health, Grant/Award Numbers: R01HD088105-01A1, U01HD055651 and P50HG007257

Abstract

Objective: There are concerns regarding the potential harms in receipt of prenatal chromosome microarray (CMA) results, particularly variants of uncertain significance (VUS). We examined the influence that the return of genomic results had on parental well-being and perceptions of children's development.

Methods: Parents (n = 138) of 83 children who underwent prenatal chromosomal microarray testing completed questionnaires assessing perception of children's development, parent-child attachment, parental mood, parenting competence, marital satisfaction, satisfaction with the decision to undergo testing, and attitudes about genetics at age 12 and/or 36 months. Responses were compared between parents who received normal/likely benign results and VUS results.

Results: Compared to normal/likely benign results, parents who received VUS results rated their child as less competent on the BITSEA scale at 12 ($\beta = -1.65$, $P = .04$) though not 36 months ($P = .43$). There were no differences in parent mood, marital satisfaction, or parenting competence. At 36 months, parents in the VUS group reported less satisfaction with their decision to undergo genetic testing ($\beta = 1.51$, $P = .02$).

Conclusion: Chromosome microarray VUS results have limited impact on parental well-being and perception of children's development. However, the initial diminished perception of child competency and later dissatisfaction with genomic testing indicate the need to assist parents in coping with ambiguous results.

1 | INTRODUCTION

Molecular cytogenetics has advanced over the last decade and allowed for the detection of copy number variants (CNVs) that were previously unrecognized by conventional cytogenetics. In a previous study, the clinical utility of prenatal chromosome microarray (CMA) testing was evaluated in 4400 individuals undergoing chorionic villus sampling (CVS) and amniocentesis for fetal karyotype. In comparison

to traditional fetal karyotype, CMA detected additional clinically significant CNVs in 1.7% of the cases,¹⁻³ which led the American College of Obstetricians & Gynecologists to recommend that CMA be made available to every woman undergoing prenatal diagnostic testing.⁴ During the first 10 years of clinical postnatal use, polymorphic and benign CNVs have been identified and differentiated from pathologic CNVs associated with congenital anomalies,⁵⁻⁷ neurological, and psychiatric diseases.⁸⁻¹⁶ Many CNVs were initially classified as variants of uncertain significance (VUS) until large sets of population-based CNV data were available. The delineation of the spectrum of manifestations, frequency, and

Preeya Desai and Hannah Haber shared first author role.
Catherine Monk and Wendy K. Chung shared senior author role.

severity of symptoms is still incomplete for many rare CNVs, especially regarding manifestations in adults.

The introduction of CMA into prenatal care aims to increase reproductive autonomy by providing clinically relevant genomic information that can enhance parents' decision-making capacity by increasing diagnostic yield and allowing for targeted surveillance of associated clinical features to intervene early and improve outcomes.⁸ However, there are ethical concerns regarding potential harms caused to parents and their infants in receiving ambiguous VUS prenatal results. Although the frequency of CMA VUS will decrease over time, the overall prevalence of VUS CNVs is currently approximately 1%.¹⁷⁻²⁰ Furthermore, as the scope of prenatal genomic testing increases and expands to exome/genome sequencing, couples may have the option to receive more genetic information, and a significant fraction could be of uncertain significance, especially for patients of non-European ancestry.

Prospective parents receiving VUS results often do not anticipate the psychological and decision-demanding difficulties associated with uncertainty.¹⁸ Studies have described that upon receiving VUS results, parents report feeling a lack of support,²¹ a lack of preparedness,²² and frustration over the uncertainty and limits in medical knowledge related to VUS.²³ Of particular concern is the potential negative impact on parental psychological well-being and stress^{24,25} that can lead to mood changes, anxiety, and parenting-associated distress.²⁶⁻³³ Emerging research suggests that VUS results are associated with parents anxiously monitoring their infants, often enrolling them in early intervention programs or ongoing medical assessments.³³ The VUS results may modify parents' perceptions of their child based on the anticipation of a "damaged" child and could alter the parent-child relationship, potentially contributing to altered behavioral development. While research has been conducted on parental perspectives of the prenatal CMA processes and how receipt of CMA results affects parental stress and anxiety (specifically related to child development), little research has investigated the association between the individual genomic results and parental perceptions of children's behavior, social interaction, and health beyond early infancy.

We sought to determine if the receipt of prenatal CMA results, particularly VUS results, alters parents' perception of their child and/or modifies parental behavior and mood. We surveyed parents from the landmark Wapner et al prenatal chromosome microarray study¹ when their infants were 12 months and/or 36 months of age and assessed (1) parental perceptions of the infant's health, behavior, and neurocognitive development; (2) parental perceptions of their parenting competence, the parent-child relationship, and their own well-being; and (3) parental understanding of genetics, tolerance of ambiguity, and belief in genetic essentialism—the supremacy of genetics in determining children's developmental outcomes. We aimed to analyze the data according to the pathogenicity of the CNV result (normal/likely benign or VUS).

2 | METHODS

2.1 | Participants

Participants with pathogenic/likely pathogenic (mothers and/or fathers of 27 children) or VUS (mothers and/or fathers of 63 children)

What's already known about this topic?

- Studies have examined parental perspectives of prenatal chromosome microarray (CMA) testing, and how the CMA results received affect parental stress, mood, and anxiety.

What does this study add?

- This study assesses prenatal CMA testing in relation to parental perceptions of child outcomes up to children at age 36 months old. Little research has investigated the impact of individual genomic results on parental perceptions of children's behavior and health beyond early infancy.

prenatal results in the Wapner et al prenatal chromosome microarray study were invited to participate in this ancillary study at the 12-month follow-up session of the main CMA study.¹ Parents were enrolled upon mail return of their signed consent, and the study was approved by the Columbia University Institutional Review Board. In addition, patients with contemporaneous pregnancies with the same distribution of indications for chromosome microarray testing as in the Wapner study and normal/likely benign (normal/LB) prenatal CMA results were recruited through the Columbia University Division of Maternal Fetal Medicine and the Center for Prenatal Pediatrics and were invited to participate by their obstetricians and/or genetic counselors at 12 months postpartum. No variants were reclassified during the study, and none of the participants received mixed results.

2.2 | Study overview

Mothers and/or fathers completed questionnaires online at 12 months postpartum, 36 months postpartum, or at both time points (Table 1). Twenty children had parent reports from both the mother and father

TABLE 1 Total parent reports per child by time point

Parents Report per Child	N
12 months only: mother	11
12 months only: father	2
12 months only: mother + father	10
36 months only: mother	11
36 months only: father	1
36 months only: mother + father	23
12 months: mother	2
36 months: mother + father	
12 months: mother plus father	2
36 months: father	
12 months: mother + father	6
36 months: mother	
12 and 36 months: mother + father	21
12 and 36 months: mother	5

at 12 and 36 months. Seventeen children had both parent reports at 36 months only. Eight children had both parent reports at 12 months only. The remaining children had either a mother or a father report at 12 months, 36 months, or both.

Participants reported on their age, relationship status, race, ethnicity, and education level at the time of their first survey completion. The following measures were assessed at 12 and 36 months: Maternal Postnatal Attachment Questionnaire (MPAS), Brief Infant-Toddler Social and Emotional Assessment (BITSEA), the Vulnerable Child Scale (VCS), Profile of Mood States (POMS), Parent Sense of Competence Scale (PSOC), Golombok Rust Inventory of Marital State (GRIMS), Disclosure of Results to Others, Secrecy about Results, Decision Satisfaction Scale, Revised Scale of Ambiguity Tolerance, genetic essentialism, general understanding of genetics, and accuracy of understanding of results (both developed for this study). See Table 2 for detailed description of each study instrument used.

2.3 | Statistical analysis

Unadjusted between-group comparisons (VUS versus normal/LB) were performed using Wilcoxon's rank-sum test, Kruskal-Wallis, and Fisher's exact test, as appropriate, to compare demographic characteristics for the participants who completed only the infant behavior questionnaires at 1 time point versus those who completed both 12 and 36-month infant behavior questionnaires.

For each outcome, mixed effect regression models separately compared group differences in the parental responses. To account for the potential correlation of a mother and father reporting on the same child, a random intercept was included in the models. In all models, parent gender, race/ethnicity (nonwhite versus white), education (bachelor's or lower versus master's or higher), employment status (full time versus other), and child sex were adjusted as covariates. Group difference in the parental response change over time was compared using mixed effect regression. Each regression included time (12 versus 36 months), group, and time-by-group interaction as fixed effects. To account for intrasubject and intrafamily correlation, nested random effects that allow for varying intercepts for each subject within a family were included in the models. For the significant outcomes, we repeated the same model in the subset of the participants who completed both 12 and 36-month infant behavior questionnaires to ensure that the results were not driven by participants with missing values at either time point.

Three parent trait variables (genetic essentialism, genetic knowledge, and tolerance of ambiguity) were examined as moderators in relation to the 17 parent responses; genetic essentialism was significantly associated with 6 and 13 outcomes at 12 and 36 months, respectively, and considered as an independent variable as well as in interactions with group in models.

3 | RESULTS

A total of 158 parents of 94 unique children agreed to participate in this study. Table 3 shows enrollment data of children by diagnostic

group and sex. Of those who did not agree to participate in this ancillary study, a greater relative proportion received pathogenic prenatal test results. The clinical indication for undergoing the CMA was known from the Wapner study enrollment. As shown in Table 4, in 55% with pathogenic results, prenatal microarray testing was conducted because of an ultrasound anomaly. In those who received VUS and normal/LB results, the most common reason for prenatal microarray testing was advanced maternal age (42% and 50%, respectively) (Table 4). Because parents of only 11 children with pathogenic results agreed to participate in this study, the pathogenic group was not included in analyses. This reduced the number of parents by 20 so that analyses were based on the 138 parents of 83 unique children from the VUS and normal/LB groups.

As represented in Table 5, the majority of participants were married, white/Caucasian, and not Hispanic/Latino. The average age was 38.1 years. There were no CNV return result group differences in demographic variables (eg, age, marital status, race, ethnicity, education level, offspring sex) (all P s > .16).

3.1 | Distribution of parent and child outcomes

Table 6 shows average values for parent report of child behavior, parenting competence, attachment, perceived child vulnerability, and parent mood at 12 and 36 months. On average, parents rated their children as competent and without many problems and had minimal levels of distress (see Table 2 for details on assessments used).

3.2 | Child outcomes by CNV results returned group status

Across 6 surveys of parental perceptions of child development and attachment to the child, there was 1 significant main effect of group status related to outcomes. Compared to the normal/LB group, parents in the VUS group rated their child as less competent on the BITSEA scale at 12 months ($\beta = -1.66$, $P = .04$) though not 36 months ($P = .37$) (see Figure 1). For the BITSEA competence scale, the of-concern cutoff point is scores <11, indicating the presence of a socioemotional competency delay. A lower score reflects less competence.³⁴ At 12 months, VUS parents' ratings of their children were at the cutpoint, indicating minimal expected competence (11 on the scale) judged in the clinical range. Data show that health care professionals will refer approximately 7% of these children for further psychosocial evaluation.³⁵

3.3 | Parent views of child outcomes by CNV results returned status over time

Both the normal/LB and VUS groups increased in ratings of child competence on the BITSEA from 12 to 36 months ($\beta = 2.61$, $P < .0001$, and $\beta = 4.12$, $P < .0001$, respectively), though the VUS group showed a significantly larger increase compared to the normal/LB group ($\beta = 1.51$, $P = .05$) (Figure 1).

TABLE 2 Description of instruments

Instrument	Description	Reference
Maternal Postnatal Attachment Scale (MPAS)	A 19-item self-report questionnaire that measures feelings of attachment toward a child. Questions are scored on a 3, 4, or 5-point scale, with a higher score indicating a greater sense of attachment. In addition to a total score, there are subsets of quality of attachment, absence of hostility, and pleasure of interaction. The MPAS has good internal consistency and reliability.	Condon, J. T. and C. J. Corkindale (1998). The assessment of parent-to-infant attachment: Development of a self-report questionnaire instrument. <i>Journal of Reproductive and Infant Psychology</i> 16(1): 57-76.
Brief Infant-Toddler Social and Emotional Assessment (BITSEA)	A 42-item parent-report measure comprising 2 scales: 11 items assess socioemotional competence and 31 items assess problems. Parents rate each item on a 3-point scale (0 = not true/rarely, 1 = somewhat true/sometimes, 2 = very true/always). The range of scores is 0 to 33 for competence and 33 to 93 for problems. The BITSEA has demonstrated good construct validity and clinical validity in discriminating children with clinically significant problems from matched control children	Carter, A. S., et al. (2004). Assessment of young children's social-emotional development and psychopathology: recent advances and recommendations for practice. <i>Journal of Child Psychology and Psychiatry</i> 45(1): 109-134. Briggs-gowan, M. J., et al. (2002). Brief Infant-Toddler Social and Emotional Assessment (BITSEA) manual, version 2.0.
Vulnerable Child Scale (VCS)	A 16-item parent-report measure of parental perceptions of child vulnerability. Scored on a 4-point scale ranging from 1 to 4 (definitely false, mostly false, mostly true and definitely true). Two items are scored in the reverse direction. Total scores range from 16 to 64, with lower scores reflecting higher perceived vulnerability. The VCS has good validity and internal reliability, with an alpha reported to be .75.	Forsyth, B. W., et al. (1996). The child vulnerability scale: an instrument to measure parental perceptions of child vulnerability. <i>J Pediatr Psychol</i> 21(1): 89-101.
Profile of Mood States (POMS)	A 65-item self-report measure of 6 different affective states: anger/hostility, tension/anxiety, depression/dejection, vigor/activity, fatigue/inertia, and confusion/bewilderment. Each item is rated on a scale of 0 (not at all) to 4 (extremely). Scores range from 0 to 260, with higher scores indicating a greater level of distress. The depression subscale consists of 15 items, with a range of scores from 0 to 60. Internal consistency is reported at 0.63 to 0.96 Cronbach alpha rating.	McNair, D. M. (1971). Manual profile of mood states. Educational & Industrial testing service.
Parenting Sense of Competence Scale	A 16-item self-report measure of parental competence in satisfaction and efficacy. The satisfaction section examines the parents' anxiety, motivation, and frustration, while the efficacy section assesses the parents' competence, capability levels, and problem-solving abilities in their parental role. A higher score indicates a greater sense of parenting competence.	Gibaud-Wallston, J., & Wandersman, L. P. (1978). Parenting sense of competence scale. Lawrence Erlbaum Associates. Chicago
Golombok Rust Inventory of Marital States (GRIMS)	A 28-item self-report measure assessing the quality of a relationship between a man and woman who are married or living together. Each item is scored on a 4-point Likert scale ranging from 0 to 3 (strongly disagree, disagree, agree, strongly agree). A higher score indicates a more problematic relationship. The GRIMS has good validity and reliability (.90 for women and .92 for men).	Rust, J., et al. (1986). The golombok rust inventory of marital state (GRIMS). <i>Sexual and Marital Therapy</i> 1(1): 55-60.
Disclosure of Results to Others	A 5-item self-report measure determining to whom, if anyone, an individual disclosed their health results.	Ashida, S., et al. (2009). Disclosing the disclosure: Factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. <i>Journal of health communication</i> 14(8): 768-784.
Secrecy About Results	A 5-item self-report measure of an individual's attitude toward disclosing a health diagnosis. Each question is rated on a 6-point Likert scale from 1 (strongly agree) to 6 (strongly disagree). A higher score corresponds to an endorsement of secrecy. The SAR has good validity, with an alpha of .71.	Link, B. G., et al. (1989). A modified labeling theory approach to mental disorders: An empirical assessment. <i>American sociological review</i> : 400-423.
Decision Satisfaction Scale	A 10-item self-report measure assessing levels of satisfaction about a decision. Each item is answered on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). A higher score indicates a more positive attitude toward the decision.	*Sainfort F, Booske BC. Measuring postdecision satisfaction. <i>Med Decis Making</i> 2000; 20:510-61. AND O'Connor AM. Validation of a decisional conflict scale. <i>Med Decis Making</i> 1995; 15:25-30.
Revised Scale for Ambiguity Tolerance (RSAT)	A 20-item self-report measure for the capacity for tolerating ambiguity. Each item is answered with true or false. The questionnaire is scored for high ambiguity tolerance. The RSAT has excellent reliability (.86) and validity.	Mac Donald Jr, A. P. (1970). Revised scale for ambiguity tolerance: Reliability and validity. <i>Psychological reports</i> 26(3): 791-798.
Genetic Essentialism	A 6-item self-report questionnaire measuring participant's thoughts about his/her genetic makeup. Each question is rated on a 4-point Likert scale (1 = strongly disagree; 4 = strongly agree). Cronbach alpha was .76 among N = 70 people with epilepsy in a baseline survey.	Klitzman, R., Appelbaum, P. S., Fyer, A., Martinez, J., Buquez, B., Wynn, J., & Chung, W. K. (2013). Researchers' views on return of incidental genomic research results: qualitative and quantitative findings. <i>Genetics in Medicine</i> , 15 (11), 888-895. AND Phelan, J. C. (2005). Geneticization of

(Continues)

TABLE 2 (Continued)

Instrument	Description	Reference
Genetic Knowledge	Created for purpose of this study	Deviant Behavior and Consequences for Stigma: The Case of Mental Illness*. Journal of Health and Social Behavior, 46(4), 307-322.

TABLE 3 Enrollment of child by group

Group	Not Enrolled (%)	Enrolled (%)	N
Pathogenic	16 (59.3%)	11 (40.7%)	27
VUS	28 (44.4%)	35 (55.6%)	63
Normal/likely benign	21 (30.4%)	48 (69.6%)	69
Total	65 (40.9%)	94 (59.1%)	159

3.4 | Parent report of well-being by CNV return group status

At the 12 and 36-month assessments, there were no group differences in parent mood, marital satisfaction, or parenting sense of competence (all P s > .07). However, at 36 months, parents who received VUS compared to normal/LB results reported significantly less satisfaction with their decision to undergo genetic testing ($\beta = -3.25$, $P = .02$).

3.5 | Parent trait genetic essentialism

In the group of parents who received VUS results, mothers versus fathers reported significantly higher scores of genetic essentialism ($P = .05$). Genetic essentialism was not a significant moderator in any outcomes of child development or parent mood (all P s > .11).

4 | DISCUSSION

This study investigated the potential impact of ambiguous versus normal/LB prenatal CMA results on parental perceptions of infants'/toddlers' emotional and social development, parenting competence, parent attachment, and self-reported parental mood at 12 and 36 months of the child's age. Our limited significant findings in the context of extensive examination of possible altered parent and child outcomes indicate little effect of CMA VUS results on parents'

perception of their child's development or their own well-being. Parental report of infant competency was lower in VUS parents compared to the normal/LB group at 12 months, though this difference was not present at 36 months. From 12 to 36 months of age, both groups reported increases in child competence, though the rate of increase was higher for the VUS group. However, our results show that at 36 months, though not at 12 months, parents who received VUS versus normal/LB results were significantly less satisfied with their decision to undergo prenatal CMA testing—perhaps because by that time point, they viewed their children as developing typically and regretted having gone through a period of enhanced surveillance. Traits such as genetic essentialism, genetic knowledge, and tolerance for ambiguity did not moderate the findings.

Previous qualitative studies examining the impact of prenatal CMA testing have shown that parents who receive CMA VUS results often report anxiety about their infant's development and behavior.^{19,20,33,36} Similarly, a recent study investigating parental experience of abnormal fetal ultrasound screenings described that anxiety about the results continued well after the results were proven to be false-positives, and suggest that genetics is not unique in providing ambiguous prenatal information.³⁷ Driven by fear of the potential bad outcomes that may be associated with an uncertain genetic result, parents may anxiously overexamine their infant's behavior, finding deficits when there are none. One prior study by Briggs-Gowan et al found that levels of parental worry/anxiety were associated with concerning BITSEA scores on both the social and emotional problem scale and social and emotional competency scale. Most children with worried/anxious parents (62.2%) also had BITSEA scores that fell outside of the normal range.³⁸ Interestingly, our results showed a lack of differences in self-reported parental mood between parents receiving VUS and normal/LB results. We expected parental mood, specifically parental stress and anxiety from the anticipation of a damaged child, to be significantly different between the normal/LB and the VUS groups. This was not the case, and no measure of parental mood

TABLE 4 Child sex and medical history by group

Pathogenic	11/94 (12%)	VUS	35/94 (37%)	Normal/Likely Benign	48/94 (51%)
Child Sex		Child Sex		Child Sex	
Female	4 (36%)	Female	16 (46%)	Female	26 (54%)
Male	7 (64%)	Male	19 (54%)	Male	22 (46%)
Reason for microarray test		Reason for microarray test		Reason for microarray test	
Ultrasound anomaly	6 (55%)	Ultrasound anomaly	7 (20%)	Ultrasound anomaly	9 (18%)
Family history	1 (9%)	Family history	3 (9%)	Family history	3 (6%)
Maternal age	3 (27%)	Maternal age	15 (42%)	Maternal age	24 (50%)
Positive serum screen	0 (0%)	Positive serum screen	7 (20%)	Positive serum screen	6 (13%)
Other	1 (9%)	Other	3 (9%)	Other	6 (13%)

TABLE 5 Demographics of parent participants

	Mean (SD) or %	N
Age (years) ^a	38.1 (5.5)	138
Gender		
Female	62%	80
Male	42%	58
Relationship status		
Married or living as married	96%	133
Married, not living together	1%	1
Never married	3%	4
Race		
American Indian	1%	1
Asian/Pacific Islander	6%	8
Biracial	3%	4
Black/African American	4%	6
White/Caucasian	80%	111
Other	6%	8
Ethnicity		
Hispanic/Latino	12%	17
Not Hispanic/Latino	88%	121
Education level		
Bachelors	28%	38
Doctoral	19%	26
High school graduate/GED	1%	3
Master's degree	36%	49
Other	16%	22

^aAt time of first survey completion.

was significantly different between any of the groups which may be because of our use of general versus specific stress scales and may benefit from qualitative interview of the impact of prenatal VUS results on parents.

TABLE 6 Means of parent report outcome variables at 12 and 36 months

Variable	12M					36M				
	N	Mean	Std Dev	Minimum	Maximum	N	Mean	Std Dev	Minimum	Maximum
BITSEA: Problem Scale	91	8.3	4.5	2	26	101	8.9	4.1	3	26
BITSEA: Competency Scale	91	12.0	3.2	4	18.8	101	15.1	2.4	7.8	19
Parenting Sense of Competency: Subscale 1	91	38.0	5.8	21	48	100	36.5	6.2	14	48
Parenting Sense of Competency: Subscale 2	91	40.2	6.5	25	54	100	39.5	6.9	18	54
Parenting Sense of Competency: Summary	91	78.2	10.6	46	101	100	76.1	11.6	32	102
Maternal Postnatal Attachment Scale: Quality of Attachment	91	36.6	3.1	25	42	100	35.8	3.3	24	42
Maternal Postnatal Attachment Scale: Absence of Hostility	91	17.2	1.5	11	20	100	16.2	1.6	11	20
Maternal Postnatal Attachment Scale: Pleasurable Interaction	91	22.0	2.1	16	25	100	21.6	2.1	16	25
Vulnerable Child Scale	90	50	5.4	35	58	100	51.1	5.3	32	59.7
Profile of Mood States: Tension	90	15.9	6.0	9	37	98	15.9	5.9	9	41
Profile of Mood States: Depression	90	20.4	9.6	15	62	98	20.0	8.8	15	70
Profile of Mood States: Anger	90	16.2	6.8	12	45	99	16.0	6.0	12	43
Profile of Mood States: Fatigue	90	15.6	6.2	7	35	98	14.6	5.6	7	35
Profile of Mood States: Confusion	90	13.3	4.4	7	29	98	12.5	3.7	7	29
Profile of Mood States: Vigor	90	23.3	6.8	9	40	98	23.4	7.1	8	38
Profile of Mood States: Total Mood Disturbances	90	58.1	31.6	19	191	98	55.6	29.8	16	209
Decision Satisfaction Scale	90	42.7	6.3	18	50	98	41.9	6.9	19	50

The significant group difference in parental perception of infant competency observed at 12 months was not present at 36 months, a period when both groups of parents increased their judgment of their child's competence. Consistent with previous studies highlighting parental coping in those who underwent CMA, we suggest that parental perception of infant competency (measured by BITSEA) is less affected by VUS-related vigilance as the infant progresses in development.³³ As additional developmental milestones are reached normally, parents become less anxious, scrutinize their child less, and, therefore, report children as more competent. Despite uncertain genetic results, parents of young children with VUS results remain hopeful about their child's normal development as the child demonstrates typical levels of competence.³⁹ Similar to another study, which surveyed parents 6 months after the receipt of CMA results, in our study, at 36 months, parents who received VUS results were less satisfied with their decision to undergo CMA testing.³⁶ We suggest that this dissatisfaction is because of frustration with the current limitations in our ability to interpret genetic results, the influence of ambiguity on parental psychology and parenting styles promoting "watchful waiting,"³⁶ and parents' increased sense of child competency as the child gets older. As the child appears more competent, parents may feel regretful of the unnecessary stress and anxiety brought about by the testing process. This experience should be considered as we decide which results to return from prenatal exome and genome sequencing and try to optimize the utility of the test.

4.1 | Limitations

Our research study has some limitations. As with a large proportion of genetic studies, our cohort of parents was demographically homogeneous. The majority of participants were married or living as married, self-reported as white/Caucasian, and had received at least a college-level education. Future research should investigate parental




FIGURE 1 Scores on parent report of child competency through BITSEA. A higher score indicates greater perceived competency. There is a significant difference in competency scores between VUS and normal/LB parents at 12 months ($P = .04$), though not 36 months ($P = .37$). Scores for the normal/LB and VUS groups increased from 12 to 36 months ($\beta = 2.61$, $P < .0001$, and $\beta = 4.12$, $P < .0001$, respectively), but the VUS group's scores increased significantly more ($P = .05$) [Colour figure can be viewed at wileyonlinelibrary.com]

perceptions in other racial and socioeconomic backgrounds, especially given that VUS results are currently more common in other racial/ethnic groups.⁴⁰ As providers gained experience with CMA testing, their counseling, explanations, and setting of expectations may have changed over time. We did not record any parental biological markers of stress, which could have been used to further quantify our parental stress and anxiety tests, a subtest of the broader mood state test. We only had 11 children in our pathogenic CNV-returned results group and, therefore, were unable to include this group in statistical analyses. The small sample size of this study is an additional limitation. As a result, further corroboration is needed for our findings.

4.2 | Future clinical significance

Our minimal positive findings suggest that receipt of CMA VUS results has limited impact on the parental perception of children's development and behavior by 36 months of age. However, we highlight some potential improvements for the clinical management of prenatal CMA testing based on the perceptions of child competency. Parents receiving VUS results initially perceived their infants as less competent at 12 months. Previous studies suggest that parents of children with VUS results may engage in additional medical and developmental surveillance during early life stages.³³ We suggest that parents receiving VUS results be encouraged to follow up with a pediatric geneticist who can help manage expectations, provide feedback, and alleviate some of the surveillance burden that parents experience. When possible, setting expectations about the large fraction of VUS that are reclassified to likely benign/benign can be helpful. More guidance should be provided to assist parents through coping with ambiguous results, monitoring how parents are coping with the results, how they are perceiving their child's development, and providing updates on the classification of the CNV as new data are available.

It is somewhat concerning that at 36 months postpartum, parents with VUS results felt greater dissatisfaction with the decision to undergo testing, although the frequency of VUS in the study overall was low. It would be of interest to determine whether decision satisfaction continues to change over time for these parents. Efforts

should be made to allow parents to indicate how much detail they would like to receive about CMA and other genomic results, and whether they want to know about inconclusive findings. Education in the pre-test counseling sessions is critical to providing parents with the autonomy, knowledge, and anticipation of possible outcomes to make the right decision for themselves. This educational session can be challenging if coincident with provision of a serious anatomic fetal anomaly and, for some patients, supplementary educational materials including videos or written materials may be helpful.

Chromosome microarray is the first application of large-scale genomic analysis in the prenatal setting. Large-scale analysis will be offered to more as cell-free CMA testing becomes routinely performed on maternal blood. Much more expansive genomic analysis, including large panels, exome, and genome sequencing, will result in parents facing similar challenges of ambiguity, though with much more data, and the challenges may become even more complex.

ACKNOWLEDGEMENTS

We thank the families that participated in this study. Funding was provided by National Institute of Health: U01 HD055651, P50HG007257, and R01HD088105-01A1.

CONFLICTS OF INTEREST

None declared.

ORCID

Preeya Desai  <http://orcid.org/0000-0003-0432-5745>

REFERENCES

1. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. *N Engl J Med*. 2012;367(23):2175-2184.
2. Hillman SC, McMullan DJ, Hall G, et al. Use of prenatal chromosomal microarray: Prospective cohort study and systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2013;41(6):610-620.
3. Shaffer LG, Rosenfeld JA. Microarray-based prenatal diagnosis for the identification of fetal chromosome abnormalities. *Expert Rev Mol Diagn*. 2013;13(6):601-611.

4. Committee Opinion No.682: Microarrays and next-generation sequencing technology: The use of advanced genetic diagnostic tools in obstetrics and gynecology. *Obstet Gynecol.* 2016;128(6):e262-e268.
5. Richards AA, Garg V. Genetics of congenital heart disease. *Curr Cardiol Rev.* 2010;6(2):91-97.
6. Sanna-Cherchi S, Kiryluk K, Burgess KE, et al. Copy-number disorders are a common cause of congenital kidney malformations. *Am J Hum Genet.* 2012;91(6):987-997.
7. Southard AE, Edelmann LJ, Gelb BD. Role of copy number variants in structural birth defects. *Pediatrics.* 2012;129(4):755-763.
8. Lawson KL, Pierson RA. Maternal decisions regarding prenatal diagnosis: Rational choices or sensible decisions? *J Obstet Gynaecol Can.* 2007;29(3):240-246.
9. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. *Science.* 2007;316(5823):445-449.
10. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. *Nature.* 2008;455(7210):232-236.
11. Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and Autism. *N Engl J Med.* 2008;358(7):667-675.
12. Heinzen EL, Radtke RA, Urban TJ, et al. Rare deletions at 16p13.11 predispose to a diverse Spectrum of sporadic epilepsy syndromes. *Am J Hum Genet.* 2010;86(5):707-718.
13. Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in epilepsy: Novel susceptibility loci in idiopathic generalized and focal epilepsies. *PLoS Genet.* 2010;6(5):e1000962.
14. Cooper GM, Coe BP, Girirajan S, et al. A copy number variation morbidity map of developmental delay. *Nat Genet.* 2011;43(9):838-846.
15. Kaminsky EB, Kaul V, Paschall J, et al. An evidence-based approach to establish the functional and clinical significance of CNVs in intellectual and developmental disabilities. *Gen Med.* 2011;13(9):777-784.
16. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo copy number variations (CNVs), including duplications of the 7q11.23 Williams-Beuren syndrome region, are strongly associated with autism. *Neuron.* 2011;70(5):863-885.
17. Hillman SC, Pretlove S, Coomarasamy A, et al. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: A systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2011;37(1):6-14.
18. Reiff M, Bernhardt BA, Mulchandani S, et al. "What does it mean?": Uncertainties in understanding results of chromosomal microarray testing. *Genet Med.* 2012;14(2):250-258.
19. Jez S, Martin M, South S, Vanzo R, Rothwell E. Variants of unknown significance on chromosomal microarray analysis: parental perspectives. *J Community Genet.* 2015;6(4):343-349.
20. Kiedrowski LA, Owens KM, Yashar BM, Schuette JL. Parents' perspectives on variants of uncertain significance from chromosome microarray analysis. *J Genet Couns.* 2016;25(1):101-111.
21. Wilkins EJ, Archibald AD, Sahhar MA, White SM. "It wasn't a disaster or anything": Parents' experiences of their child's uncertain chromosomal microarray result. *Am J Med Genet A.* 2016;170(11):2895-2904.
22. Werner-Lin A, Barg FK, Kellom KS, et al. Couple's narratives of communion and isolation following abnormal prenatal microarray testing results. *Qual Health Res.* 2016;26(14):1975-1987.
23. Giarelli E, Reiff M. Mothers' appreciation of chromosomal microarray analysis for autism spectrum disorder. *J Spec Pediatr Nurs.* 2015;20(4):244-258.
24. Shuster E. Microarray genetic screening: A prenatal roadblock for life? *Lancet.* 2007;369(9560):526-529.
25. Pergament E. Controversies and challenges of array comparative genomic hybridization in prenatal genetic diagnosis. *Genet Med.* 2007;9(599):596-599.
26. Clarkeburn H. Parental duties and untreatable genetic conditions. *J Med Ethics.* 2000;26(5):400-403.
27. Tercyak KP, Johnson SB, Roberts SF, Cruz AC. Psychological response to prenatal genetic counseling and amniocentesis. *Patient Educ Couns.* 2001;43(1):73-84.
28. Kowalcek I, Mühlhoff A, Bachmann S, Gembruch U. Depressive reactions and stress related to prenatal medicine procedures. *Ultrasound Obstet Gynecol.* 2002;19(1):18-23.
29. Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. *J Consult Clin Psychol.* 2002;70(3):784-797.
30. Kaiser AS, E. Ferris L, Katz R, et al. Psychological responses to prenatal NTS counseling and the uptake of invasive testing in women of advanced maternal age. *Patient Educ Couns.* 2004;54(1):45-53.
31. Allison SJ, Stafford J, Anumba DOC. The effect of stress and anxiety associated with maternal prenatal diagnosis on fetomaternal attachment. *BMC Womens Health.* 2011;11(1):33-33.
32. Reiff M, Bugos E, Giarelli E, et al. "Set in stone" or "ray of hope": Parents' beliefs about cause and prognosis after genomic testing of children diagnosed with ASD. *J Autism Dev Disord.* 2017;47(5):1453-1463.
33. Werner-Lin A, Walser S, Barg FK, Bernhardt BA. "They can't find anything wrong with him, yet": Mothers' experiences of parenting an infant with a prenatally diagnosed copy number variant (CNV). *Am J Med Genet A.* 2017;173(2):444-451.
34. Briggs-Gowan MJ, Carter AS, Irwin JR, Wachtel K, Cicchetti DV. The brief infant-toddler social and emotional assessment: Screening for social-emotional problems and delays in competence. *J Pediatr Psychol.* 2004;29(2):143-155.
35. Kruizinga I, Jansen W, Mieloo CL, Carter AS, Raat H. Screening accuracy and clinical application of the brief infant-toddler social and emotional assessment (BITSEA). *PLoS One.* 2013;8(8):e72602.
36. Bernhardt BA, Soucier D, Hanson K, Savage MS, Jackson L, Wapner RJ. Women's experiences receiving abnormal prenatal chromosomal microarray testing results. *Genet Med.* 2013;15(2):139-145.
37. Larsson A-K, Svalenius EC, Lundqvist A, Dykes AK. Parents' experiences of an abnormal ultrasound examination—vacillating between emotional confusion and sense of reality. *Reprod Health.* 2010;7(1):10-10.
38. Briggs-Gowan MJ, Carter AS. Social-emotional screening status in early childhood predicts elementary school outcomes. *Pediatrics.* 2008;121(5):957-962.
39. Whitmarsh I, Davis AM, Skinner D, Bailey DB Jr. A place for genetic uncertainty: Parents valuing an unknown in the meaning of disease. *Soc Sci Med.* 2007;65(6):1082-1093.
40. Saulsberry K, Terry SF. The need to build trust: A perspective on disparities in genetic testing. *Genet Test Mol Biomarkers.* 2013;17(9):647-648.

How to cite this article: Desai P, Haber H, Bulafka J, et al. Impacts of variants of uncertain significance on parental perceptions of children after prenatal chromosome microarray testing. *Prenatal Diagnosis.* 2018;38:740-747. <https://doi.org/10.1002/pd.5323>